New approaches in topical treatment of atopicdermatitis in children



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

На основании данных литературы и собственных исследований рассмотрены особенности патогенеза
и современные технологии наружной терапии атопического дерматита у детей, проведен анализ опыта
клинического применения средств лечебной дерматологической косметики, предложена тактика
местного лечения атопического дерматита у детей с их использованием.

About the authors

G I Smirnova

Email: smirnov@nczd.ru

G I Smirnova

I.M. Sechenov M edical A cademy

I.M. Sechenov M edical A cademy

References

  1. Смирнова Г.И. Современная концепция лечения атопического дерматита / ММА им. И.М. Сеченова. М. 2006, 132 с.
  2. Bieber T., Novak N. Pathogenesis of atopic dermatitis: new developments. Curr. Allergy Asthma Rep. 2009, v. 9, No. 4, p. 291-294.
  3. Смирнова Г.И. Аллергодерматозы у детей. М.: БУК, Лтд., 1998. 300 с.
  4. Novak N. New insights into the mechanism and management of allergic diseases: atopic dermatitis. Allergy. 2009, v. 64, No. 2, p. 265-275.
  5. Elias P.M., Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 2009, v. 9, No. 5, p. 437-446.
  6. Homey B., Meller S., Savinko T. et al. Modulation of chemokines by staphylococcal superantigen in atopic dermatitis. Chem. Immunol. Allergy. 2007, v. 93, No. 1, p. 181-194.
  7. Oyoshi M.K., He R., Kumar L., Yoon J., Geha R.S. Cellular and molecular mechanisms in atopic dermatitis. Adv. Immunol. 2009, v. 102, No. 1, p. 135-226.
  8. Koga C., Kabashima K., Shiraishi N. et al. Possible pathogenic role of Th17 cells for atopic dermatitis. J. Invest. Dermatol. 2008, v. 128, No. 11, p. 2625-2630.
  9. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009, v. 27, No. 4, p. 485-517.
  10. Komine M. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: keratinocytes in atopic dermatitis -their pathogenic involvement. J. Pharmacol. Sci. 2009, v. 110, No. 3, p. 260-264.
  11. Howell M.D., Kim B.E., Gao P. et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J. Allergy Clin. Immunol. 2007, v. 120, No. 1, p. 150-155.
  12. Mizutani Y., Mitsutake S., Tsuji K. et al. Ceramide biosyn-thesis in keratinocyte and its role in skin function. Biochimie. 2009, v. 91, No. 6, p. 784-790.
  13. Verdier-Sevrain S., Bonte, F. Skin hydration: a review on its molecular mechanisms. J. Cosmet. Dermatol. 2007, v. 6, No. 2, p. 75-82.
  14. O'Regan G.M., Irvine A.D. The role of filaggrin loss-of-function mutations in atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 2008. v. 8, No. 5, p. 406-410.
  15. Proksch E., Brandner J.M., Jensen J.M. The skin: an indispensable barrier. Exp. Dermatol. 2008, v. 17, No. 12, p. 1063-1072.
  16. Jensen J.M., Pfeiffer S., Witt M. et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2009, v. 123, No. 5, p. 1124-1133.
  17. Proksch E., Lachapelle J.M. The management of dry skin with topical emollients-recent perspectives. J. Dtsch. Dermatol. Ges. 2005, v. 3, No. 10, p. 768-774.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright © Pharmarus Print Media, 2010



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies